The text starts here.

News Release

July 4, 2006
For Print (PDF 106KB)

Pharmaceutical Marketing Subsidiary in Singapore Launches Operations

Eisai Co., Ltd. (Headquarters: Tokyo; President and CEO: Haruo Naito) has established a new pharmaceutical marketing subsidiary in Singapore, "Eisai (Singapore) Pte., Ltd." (ESN), which has launched pharmaceutical import and marketing business.

Previously, Eisai's pharmaceutical import and marketing business in Singapore was handled by Eisai Asia Regional Services Pte. Ltd. (EARS; Head office: Singapore; President: Hiroshi Kimura), but EARS has recently transferred this business to ESN.

By launching operations with this new company, Eisai aims to strengthen its pharmaceutical business in Singapore and further contribute to patients' value in the region.

EARS will renew its operation as a holding company assuming specific function of the seven local subsidiaries in the Asian region, including this newly established ESN in Singapore and existing six others in China, Thailand, Malaysia, the Philippines, Hong Kong and India.

[Profile of Eisai (Singapore) Pte. Ltd.]
Capital :300,000 Singapore dollars (approx. 22,000,000 yen)
Location :Singapore
President :Celine Ting
Scope of Business :Import, marketing, and promotion of pharmaceuticals
Capital Alliance :100% subsidiary of EARS

Corporate Communications Department
Eisai Co., Ltd.
TEL: +81-3-3817-5120